SLA Pharma   Report issue

For profit Phase 2 Phase 3
Founded: Liestal Switzerland (1997)
Status: No NME R&D (1997)

Organization Overview

First Clinical Trial
2005
NCT00509639
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

S.L.A. Pharma | S.L.A. Pharma AG

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenomatous Polyposis Coli (Phase 3)

Adenomatous Polyps (Phase 3)

Chronic Pain (Phase 2)

Colorectal Neoplasms (Phase 3)

Constipation (Phase 2)

Crohn Disease (Phase 3)

Fecal Incontinence (Phase 3)

Fissure in Ano (Phase 3)

Nasopharyngeal Neoplasms (Phase 3)

Pilonidal Sinus (Phase 2)

Polyps (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial APIs: 6